Meeting the goal of concurrent adolescent and adult licensure of HIV prevention and treatment strategies

Journal of Medical Ethics 43 (12):857-860 (2017)
  Copy   BIBTEX

Abstract

The ability of adolescents to access safe and effective new products for HIV prevention and treatment is optimised by adolescent licensure at the same time these products are approved and marketed for adults. Many adolescent product development programmes for HIV prevention or treatment products may proceed simultaneously with adult phase III development programmes. Appropriately implemented, this strategy is not expected to delay licensure as information regarding product efficacy can often be extrapolated from adults to adolescents, and pharmacokinetic properties of drugs in adolescents are expected to be similar to those in adults. Finally, adolescents enrolled in therapeutic HIV prevention and treatment research can be considered adults, based on US Food and Drug Administration regulations and the appropriate application of state law. The FDA permits local jurisdictions to apply state and local HIV/sexually transmitted infection minor treatment laws so that adolescents who are HIV-positive or at risk of contracting HIV may be enrolled in therapeutic or prevention trials without obtaining parental permission.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,252

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Analytics

Added to PP
2017-11-24

Downloads
33 (#462,035)

6 months
9 (#259,174)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations